Subscribe To
Tonix Pharmaceuticals Expedites Fibromyalgia and Chronic Migraine Programs
Streamlining Phase 3 Fibromyalgia and Phase 2 Chronic Migraine Trials by Eliminating Interim Analyses Topline Results Expected for Both Programs in Fourth Quarter 2023 CHATHAM, N.J., April 13, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it is eliminating the interim analyses in its registration-enabling, confirmatory […] The post Tonix Pharmaceuticals Expedites Fibromyalgia and Chronic Migraine Progr...
Read More
Posted: Apr 13 2023, 11:00
Author Name: forextv
Views: 082038